About Biodesix Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.biodesix.com/
Frequently Asked Questions
What is the 52-week range for BDSX?
The 52-week high is $31.97 and the 52-week low is $5.26.
What is the P/E ratio for BDSX?
The P/E ratio data is currently unavailable.
What is the dividend yield for BDSX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -164.87%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -26.97%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 10.66.
Analyst Recommendation Trends
Wall Street analyst consensus for BDSX over the last few months:
Latest BDSX News
Will Thermo Fisher’s New cGMP CHO-K1 Panel and MRD Moves Change Thermo Fisher Scientific's (TMO) Narrative
Earlier this month, Thermo Fisher Scientific announced several product and collaboration updates, including the cGMP-ready Gibco CHO-K1 Catalog Panel for bioprocessing, a reseller agreement to distribute Evosep’s Eno separation platform in proteomics workflows, and expanded involvement in molecular residual disease programs with Biodesix and Memorial Sloan Kettering. Together, these moves deepen Thermo Fisher’s role across biologics manufacturing, advanced proteomics, and ctDNA-based cancer...
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertiseLOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions intended to support cancer centers and clinical laboratories. Both solutions detect circulating tum
Biodesix Announces Progress In Two Collaborative Programs For Tumor-informed And Tumor-naïve Molecular Residual Disease Solutions
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions
Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism
Biodesix has seen its fair value estimate move from US$30.83 to US$34.00, which works out to roughly a 10% uplift in the price target range used by analysts. Recent research coverage links this shift to a mix of optimism around revenue momentum and margin potential, along with some caution about execution and the timing of profitability. As you read on, you will see how these moving parts shape the current analyst narrative and what to watch as it evolves from here. Stay updated as the Fair...
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodulesLOUISVILLE, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that Brianna Phillips, Vice President of Quality and Regulatory Affairs at Biodesix, will be presenting at the upcoming Regulatory Affairs Professionals Society (RAPS) and Society of Clinical Research Asso
Biodesix: Growing Fast While Trading Below Many Diagnostics Peers
Biodesix's lung diagnostics surge with 30%+ revenue growth, 80%+ margins, and discounted valuations. Click here to read an analysis of BDSX stock now.
Biodesix to Participate in Upcoming Investor Conferences
LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences: Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference1x1 meetings onlyDate: Thursday, September 10Location: New York, NY H.C. Wainwright 28th Annual Global Investment Conference1x1 meetings onlyDate: Tuesday, September 15Location: New Y
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-12 | SCHULER JACK W | +15,000 | $24.4661 | $366,992 |
| 2026-08-11 | SCHULER JACK W | +13,700 | $24.0081 | $328,911 |
| 2026-08-10 | SCHULER JACK W | +13,900 | $24.2467 | $337,029 |
| 2026-06-30 | PATIENCE JOHN | -1,361 | - | - |
| 2026-06-30 | PATIENCE JOHN | +1,361 | - | - |
| 2026-03-31 | PATIENCE JOHN | -1,361 | - | - |
| 2026-03-31 | PATIENCE JOHN | +1,361 | - | - |
| 2026-02-23 | Vazquez Chris | -211 | $12.7756 | $2,696 |
| 2026-02-23 | Cowie Robin Harper | -535 | $12.7756 | $6,835 |
| 2026-02-23 | Hutton Scott | -1,490 | $12.7756 | $19,036 |
| 2026-02-23 | Pestano Gary Anthony | -556 | $12.7756 | $7,103 |
| 2026-02-23 | O'Kane Kieran | -535 | $12.7756 | $6,835 |
| 2026-02-20 | Vazquez Chris | -563 | - | - |
| 2026-02-20 | Vazquez Chris | +563 | - | - |
| 2026-02-20 | Cowie Robin Harper | -1,469 | - | - |
| 2026-02-20 | Cowie Robin Harper | +1,469 | - | - |
| 2026-02-20 | Hutton Scott | -4,844 | - | - |
| 2026-02-20 | Hutton Scott | +4,844 | - | - |
| 2026-02-20 | Pestano Gary Anthony | -1,528 | - | - |
| 2026-02-20 | Pestano Gary Anthony | +1,528 | - | - |
| 2026-02-20 | O'Kane Kieran | -1,469 | - | - |
| 2026-02-20 | O'Kane Kieran | +1,469 | - | - |
| 2026-02-10 | Cowie Robin Harper | -941 | $10.0841 | $9,489 |
| 2026-02-10 | Vazquez Chris | -101 | $10.0841 | $1,018 |
| 2026-02-10 | O'Kane Kieran | -584 | $10.0841 | $5,889 |
| 2026-02-10 | Pestano Gary Anthony | -540 | $10.0841 | $5,445 |
| 2026-02-10 | Hutton Scott | -3,559 | $10.0841 | $35,889 |
| 2026-02-09 | Cowie Robin Harper | -2,427 | - | - |
| 2026-02-09 | Cowie Robin Harper | -157 | - | - |
| 2026-02-09 | Cowie Robin Harper | +2,584 | - | - |
| 2026-02-09 | Vazquez Chris | -235 | - | - |
| 2026-02-09 | Vazquez Chris | -28 | - | - |
| 2026-02-09 | Vazquez Chris | +263 | - | - |
| 2026-02-09 | O'Kane Kieran | -1,527 | - | - |
| 2026-02-09 | O'Kane Kieran | -73 | - | - |
| 2026-02-09 | O'Kane Kieran | +1,600 | - | - |
| 2026-02-09 | Pestano Gary Anthony | -1,413 | - | - |
| 2026-02-09 | Pestano Gary Anthony | -68 | - | - |
| 2026-02-09 | Pestano Gary Anthony | +1,481 | - | - |
| 2026-02-09 | Hutton Scott | -9,388 | - | - |
| 2026-02-09 | Hutton Scott | -610 | - | - |
| 2026-02-09 | Hutton Scott | +9,998 | - | - |
| 2026-01-26 | SCHULER JACK W | +20,000 | $11.8032 | $236,064 |
| 2026-01-23 | SCHULER JACK W | +80,000 | $11.8084 | $944,672 |
| 2026-01-22 | SCHULER JACK W | +82,465 | $10.9569 | $903,561 |
| 2026-01-16 | Vazquez Chris | -83 | $8.1493 | $676 |
| 2026-01-16 | Pestano Gary Anthony | -298 | $8.1493 | $2,428 |
| 2026-01-16 | O'Kane Kieran | -298 | $8.1493 | $2,428 |
| 2026-01-16 | Hutton Scott | -970 | $8.1493 | $7,905 |
| 2026-01-16 | Cowie Robin Harper | -298 | $8.1493 | $2,428 |
| 2026-01-15 | Vazquez Chris | -219 | - | - |
| 2026-01-15 | Vazquez Chris | +219 | - | - |
| 2026-01-15 | Pestano Gary Anthony | -805 | - | - |
| 2026-01-15 | Pestano Gary Anthony | +805 | - | - |
| 2026-01-15 | O'Kane Kieran | -805 | - | - |
| 2026-01-15 | O'Kane Kieran | +805 | - | - |
| 2026-01-15 | Hutton Scott | -2,633 | - | - |
| 2026-01-15 | Hutton Scott | +2,633 | - | - |
| 2026-01-15 | Cowie Robin Harper | -805 | - | - |
| 2026-01-15 | Cowie Robin Harper | +805 | - | - |
| 2026-01-05 | PATIENCE JOHN | -1,143 | - | - |
| 2026-01-05 | PATIENCE JOHN | +1,143 | - | - |
| 2026-01-02 | Franchi Jean M. | +6,354 | - | - |
| 2026-01-02 | Franchi Jean M. | +8,164 | - | - |
| 2026-01-02 | Kennedy Lawrence T. Jr | +6,354 | - | - |
| 2026-01-02 | Kennedy Lawrence T. Jr | +5,443 | - | - |
| 2026-01-02 | Pestano Gary Anthony | +26,000 | - | - |
| 2026-01-02 | O'Kane Kieran | +27,000 | - | - |
| 2026-01-02 | Hutton Scott | +97,000 | - | - |
| 2026-01-02 | Cowie Robin Harper | +29,000 | - | - |
| 2026-01-02 | Vazquez Chris | +12,000 | - | - |
| 2026-01-02 | Strobeck Matthew | +6,354 | - | - |
| 2026-01-02 | Strobeck Matthew | +6,804 | - | - |
| 2026-01-02 | Kayyem Jon Faiz | +6,354 | - | - |
| 2026-01-02 | Kayyem Jon Faiz | +5,443 | - | - |
| 2026-01-02 | MASSARANY HANY | +6,354 | - | - |
| 2026-01-02 | MASSARANY HANY | +7,484 | - | - |
| 2026-01-02 | PATIENCE JOHN | +6,354 | - | - |
| 2026-01-02 | PATIENCE JOHN | +5,443 | - | - |
| 2025-11-10 | Vazquez Chris | -31 | - | - |
| 2025-11-10 | Vazquez Chris | -13 | $7.62 | $99 |
| 2025-11-10 | Vazquez Chris | +31 | - | - |
| 2025-11-10 | Pestano Gary Anthony | -69 | - | - |
| 2025-11-10 | Pestano Gary Anthony | -23 | $7.62 | $175 |
| 2025-11-10 | Pestano Gary Anthony | +69 | - | - |
| 2025-11-10 | O'Kane Kieran | -75 | - | - |
| 2025-11-10 | O'Kane Kieran | -25 | $7.62 | $191 |
| 2025-11-10 | O'Kane Kieran | +75 | - | - |
| 2025-11-10 | Hutton Scott | -611 | - | - |
| 2025-11-10 | Hutton Scott | -189 | $7.62 | $1,440 |
| 2025-11-10 | Hutton Scott | +611 | - | - |
| 2025-11-10 | Cowie Robin Harper | -158 | - | - |
| 2025-11-10 | Cowie Robin Harper | -50 | $7.62 | $381 |
| 2025-11-10 | Cowie Robin Harper | +158 | - | - |